Goldman Sachs
EDIT icon

Goldman Sachs’s Editas Medicine EDIT Stock Holding History

Goldman Sachs’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40,000
Closed -$960K – 6408
2017
Q3 		$960K Buy
40,000
+4,000
+11% +$76.1K ﹤0.01% 4605
2017
Q2 		$604K Buy
+36,000
New +$649K ﹤0.01% 4934

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs's EDIT Position: Q1 2026 in Review

Goldman Sachs reduced its Editas Medicine (EDIT) stake by 37% in Q1 2026, selling an estimated $684K and leaving 558,577 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4859.

Goldman Sachs first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $71.8M in Q4 2020. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Goldman Sachs held 558,577 shares of Editas Medicine worth $1.38M as of Q1 2026.
  • Goldman Sachs sold 323,383 Editas Medicine shares in Q1 2026, an estimated $684K.
  • Editas Medicine made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4859 holding.
  • Goldman Sachs first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Goldman Sachs's Editas Medicine position peaked at $71.8M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.